1. Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumors

   • Shira Dorot
   • James Tankel
   • Alberto Gabizon

   Original Article 08 July 2022 Pages: 109 - 114

   

2. Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients

   • Hirotsugu Kenmotsu
   • Chiyo K. Imamura
   • Yusuke Tanigawara

   Original Article 12 July 2022 Pages: 115 - 123

   

3. Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg

   • Yi-Han Chien
   • Gudrun Würthwein
   • Georg Hempel

   Original Article Open access 14 July 2022 Pages: 125 - 136

   

4. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship

   • Kazuhiko Nakagawa
   • Edward B. Garon
   • Martin Reck

   Original Article Open access 16 July 2022 Pages: 137 - 148

   

5. Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer

   • Fabrice Barlesi
   • Laure Deyme
   • Dominique Barbolosi

   Original Article 22 July 2022 Pages: 149 - 160

   

6. Mouse pharmacokinetics and metabolism of the phenylurea thiocarbamate NSC 161128

   • Emily J. Koubek
   • Rachel A. Kudgus
   • Joel M. Reid

   Original Article 27 July 2022 Pages: 161 - 174

   

7. A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies

   • Patrick M. Boland
   • Christos Fountzilas
   • Antonio Jimeno

   Original Article 29 July 2022 Pages: 175 - 187

   

8. Correction to: Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin‑based HIPEC: results of the GUTOX study

   • Loek A. W. de Jong
   • Fortuné M. K. Elekonawo
   • Nielka P. van Erp

   Correction Open access 22 June 2022 Pages: 189 - 190